Lipid A is the fat-soluble anchor of a large molecule called lipopolysaccharide (LPS) that sits on the outer surface of Gram-negative bacteria. It is the part of LPS responsible for triggering the intense immune reactions associated with bacterial infections, earning it the label “endotoxin.” When bacteria die and break apart, lipid A is released into the bloodstream, where it can activate immune cells so powerfully that it causes fever, inflammation, and in severe cases, septic shock.
Where Lipid A Sits in the Bacterial Cell
LPS is a large glycolipid made of three structural layers. Lipid A forms the innermost layer, embedded directly in the outer membrane of the bacterium. Attached to lipid A is the core oligosaccharide, a short chain of sugars. Extending outward from that is the O antigen, a long, repeating sugar chain that varies between bacterial species and helps bacteria evade the immune system. Think of the whole structure like a tree: lipid A is the root system anchoring everything into the membrane, the core sugars are the trunk, and the O antigen is the branching canopy.
Because lipid A is the hydrophobic (water-repelling) portion, it holds the entire LPS complex in place. It forms the outer leaflet of the bacterial outer membrane, creating a dense, protective barrier. This barrier makes Gram-negative bacteria naturally resistant to many antibiotics and detergents. You can separate lipid A from the rest of the LPS molecule using mild acid, which is how researchers first identified it as a distinct component.
Chemical Structure
At its core, lipid A is built on a backbone of two glucosamine (a type of amino sugar) molecules linked together. Both ends of this backbone carry phosphate groups, making the molecule bisphosphorylated. These phosphate groups carry negative charges that turn out to be critical for triggering immune responses.
Hanging off the sugar backbone are fatty acid chains, typically six in the mature form found in bacteria like E. coli and Salmonella. In Salmonella, the backbone directly carries four hydroxylated (oxygen-containing) fatty acid chains, two attached through ester bonds and two through amide bonds. The remaining fatty acids don’t connect to the backbone directly. Instead, they piggyback onto the hydroxyl groups of those first four chains, creating a branched, bushy fat structure. This dense cluster of fatty acid tails is what keeps lipid A locked into the bacterial membrane.
How Lipid A Activates the Immune System
Lipid A is the reason Gram-negative bacterial infections can escalate so quickly. Your immune system has a dedicated detection system for it, centered on a receptor called TLR4 found on the surface of immune cells. But TLR4 doesn’t actually grab lipid A on its own. Instead, a small co-receptor protein called MD-2 does the direct binding. MD-2 has a deep hydrophobic pocket that the fatty acid chains of lipid A slide into, while the sugar backbone and its phosphate groups remain exposed at the pocket entrance.
Those exposed phosphate groups are what trigger the alarm. The negatively charged phosphates on lipid A attract positively charged patches on a neighboring TLR4 molecule, pulling two TLR4 receptors together into a pair. This pairing, called dimerization, is the switch that fires off intracellular signaling. Once dimerized, TLR4 activates a cascade that causes immune cells to release a flood of inflammatory signaling molecules: TNF-alpha, interleukin-1 beta, interleukin-6, interleukin-10, and interleukin-12, among others.
In a controlled infection, this response is protective. It recruits more immune cells, raises body temperature, and helps clear the bacteria. But when large amounts of lipid A enter the bloodstream at once, the cytokine release becomes overwhelming. TNF-alpha and IL-6 in particular drive the dangerous drop in blood pressure, organ damage, and clotting problems that define septic shock.
Why Lipid A Varies Between Bacteria
Not all lipid A is equally toxic. The structure varies significantly between bacterial species, particularly in the number, length, and arrangement of fatty acid chains. The classic six-chain lipid A found in E. coli and Salmonella (with 14-carbon hydroxylated fatty acids) produces the strongest immune activation. Other Gram-negative bacteria carry lipid A with fewer chains, longer or shorter chains, or different chemical modifications, and these variants generally trigger weaker immune responses.
Some pathogenic bacteria actually exploit this variation as a survival strategy. By modifying their lipid A structure in response to environmental conditions, they can dial down the immune alarm and avoid detection. This structural flexibility is one reason certain infections are harder for the body to fight off.
How Lipid A Is Built Inside Bacteria
Bacteria assemble lipid A through a series of enzymatic steps known as the Raetz pathway, named after the biochemist Christian Raetz who mapped it out. The pathway begins inside the cell with a simple sugar-phosphate precursor and progressively adds fatty acid chains and a second glucosamine unit. A key step is the addition of the second phosphate group by an enzyme called LpxK, creating the bisphosphorylated form. The first two sugars of the core oligosaccharide are then attached before the final fatty acid chains are added, producing mature, six-chain lipid A ready to accept the rest of the LPS structure.
Every enzyme in this pathway is a potential drug target. Because lipid A is essential for the survival of most Gram-negative bacteria, blocking its production can kill the bacteria outright. Several experimental antibiotics have been designed to inhibit specific Raetz pathway enzymes, particularly LpxC, one of the early steps in the chain.
Testing for Lipid A Contamination
Because even tiny amounts of lipid A can trigger dangerous immune reactions, pharmaceutical manufacturers must test all injectable drugs and medical devices for endotoxin contamination. The standard method for over 30 years has been the Limulus amebocyte lysate (LAL) assay, which uses an extract from horseshoe crab blood. Horseshoe crab blood cells contain a clotting factor that coagulates rapidly when it contacts endotoxin, providing a sensitive and visible detection method.
Pharmacopoeias worldwide set a maximum allowable endotoxin level of 5 Endotoxin Units per kilogram of body weight per hour for intravenous drugs. Newer versions of the test use a recombinant (lab-made) version of the horseshoe crab clotting factor, reducing the need to harvest blood from wild horseshoe crabs.
Lipid A as a Vaccine Ingredient
The same immune-activating power that makes lipid A dangerous in infections makes it useful in vaccines, with one important modification. Monophosphoryl lipid A (MPLA) is a chemically altered version of lipid A with one of its two phosphate groups removed and a slight change to one fatty acid chain. These modifications reduce its toxicity to roughly 0.1% of natural LPS while preserving its ability to stimulate a strong immune response.
MPLA works through the same TLR4 signaling pathway as natural lipid A, promoting the maturation of dendritic cells (the immune cells that train other immune cells to recognize threats) and stimulating both antibody production and cellular immunity. It activates a specific branch of TLR4 signaling that favors immune priming over the dangerous inflammatory cascade. MPLA-based adjuvants are already used in licensed vaccines, including some hepatitis B and human papillomavirus vaccines, and have outperformed traditional aluminum-based adjuvants in animal studies with influenza vaccines.
Neutralizing Lipid A in Infections
One of the oldest known lipid A neutralizers is polymyxin B, an antibiotic that binds directly to lipid A with high affinity. Polymyxin B carries positive charges that are attracted to the negatively charged phosphate groups on lipid A, displacing the normal membrane structure and neutralizing its toxicity. Binding studies show polymyxin B interacts with lipid A at two different strengths, likely because lipid A exists as a mixture of forms with one or two phosphate groups. Polymyxin B is sometimes used in clinical filtration columns to remove endotoxin from the blood of patients with severe sepsis, though this approach remains more common in some countries than others.